Can you anticipate the future of US Healthcare for 2015?

At the recent R&D Leadership and Oncology Leadership Forums held in November in Boston, the opening plenary sessions and panel examined the impacts change will have on several sectors in healthcare including payers, providers, and product developers. We would like you to weigh in on your view of this future by participating in a short survey that offers you an automatic report card on how your peers view this very same future. Just click here to start the survey. (Your responses will be kept confidential).

What became a recurring theme as the Forums progressed is that the biopharmaceutical world has become significantly more uncertain in recent years. Questions around coverage and reimbursement, the ability of payors to fund healthcare programs, and ever increasing restrictions on access swirl around shifting concerns over drug safety, product differentiation, costs, generics and value. Strategic risk management issues have become uppermost with senior management in both the pharmaceutical and biotech markets.

Although the drivers of change creating this new world for biopharm are many and varied, five key drivers continue to present themselves as having maximal impact on biopharmaceutical commercialization. These can be characterized with their possible disparate endstates as follows:



Using these drivers, we have developed five plausible scenarios, or future worlds, which provide a realistic set of disparate futures representing plausible future boundaries of the commercial biopharma or healthcare marketplace.

Value-based Healthcare

• A world where the concept of value-based healthcare wins and purchasers of healthcare – employers and the government – invest in driving positive long-term health benefits for individuals rather than looking at how to simply cut costs.

Federal Tsunami

• A world where national healthcare reforms fail, and Congress introduces legislation that makes the US healthcare market to start to look like that of the nationalized systems of Europe and Canada with capitation of coverage.

Pass the Buck

• A world where both the public and private sectors of the provider market are focused on minimizing short-term costs irrelevant of the implications on the long-term health of the nation.

Data Driven Decisions

• A world where the market fully understands and embraces the new wealth of data resulting from eMR and genomics.

Physicians Rule

• A world where Federal initiatives to change healthcare have failed and, in the resulting aftermath, physicians regain control over medical decision making more as a default than through careful design.

Once again, we would like feedback from experts such as you. In particular, we wish to understand how valuable you find these scenarios in helping you think about your organization’s future strategies. Please click here to take a short survey. We will treat your responses with the highest degree of confidentiality and only publish the aggregate results, which we will share with you and other companies that participate.

Thank you in advance for participating.

Wayne A. Rosenkrans, Jr, Ph.D.
Vice President, Fuld & Company
Distinguished Fellow, MIT Center for Biomedical Innovation and
Chairman, Personalized Medicine Coalition

©Copyright Phacilitate Limited 2009